From Tysabri to bapi and back to the drawing board: Dale Schenk speaks
This article was originally published in Scrip
Executive Summary
Dale Schenk is the scientist behind both the hugely successful multiple sclerosis treatment Tysabri (natalizumab) and the much-hyped investigational Alzheimer's disease vaccination bapineuzumab, which crashed spectacularly in Phase III trials last year. Now heading up the newly independent Prothena, which was demerged from Elan late last year, he speaks to Scrip's Eleanor Malone as he embarks on his third adventure as a biotech entrepreneur.